Advertisement

Rathmell: We must put the individual at the center of our approach to ending cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Dear Colleagues,

When I started this column, I was wanting to retain the sense of connection that I had to the greater cancer community as I stepped away into a period of disconnection.

This era is built on the foundations of decades of diligent work to deeply understand the various mechanisms that drive cancer. And it will evolve further as we arrive at even deeper understandings.

I am immensely grateful to the editorial staff for giving me this outlet, and I have been elevated by the avenue it presented to hear from more voices as guest editors. Our community is even richer and more connected than I ever realized. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
W. Kimryn Rathmell, MD, PhD, MMHC
Former director, National Cancer Institute
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
Advertisement
Advertisement